[go: up one dir, main page]

TN2011000380A1 - Triazolopyridine derivatives as p38 map kinase inhibitors - Google Patents

Triazolopyridine derivatives as p38 map kinase inhibitors

Info

Publication number
TN2011000380A1
TN2011000380A1 TN2011000380A TN2011000380A TN2011000380A1 TN 2011000380 A1 TN2011000380 A1 TN 2011000380A1 TN 2011000380 A TN2011000380 A TN 2011000380A TN 2011000380 A TN2011000380 A TN 2011000380A TN 2011000380 A1 TN2011000380 A1 TN 2011000380A1
Authority
TN
Tunisia
Prior art keywords
radical
optionally substituted
map kinase
alkyl
independently
Prior art date
Application number
TN2011000380A
Other languages
English (en)
Inventor
Harry Finch
John Montana
Niel Monique Bodil Van
Chi-Kit Woo
Jamie Knight
Bohdan Waszkowycz
Original Assignee
Chiesi Farma Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42232647&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TN2011000380(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB0902651A external-priority patent/GB0902651D0/en
Priority claimed from GB0908069A external-priority patent/GB0908069D0/en
Application filed by Chiesi Farma Spa filed Critical Chiesi Farma Spa
Publication of TN2011000380A1 publication Critical patent/TN2011000380A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
TN2011000380A 2009-02-17 2011-08-03 Triazolopyridine derivatives as p38 map kinase inhibitors TN2011000380A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0902651A GB0902651D0 (en) 2009-02-17 2009-02-17 Pharmaceutical compounds and compositions
GB0908069A GB0908069D0 (en) 2009-05-11 2009-05-11 Pharmaceutical compounds and compositions
PCT/GB2010/050257 WO2010094956A1 (fr) 2009-02-17 2010-02-16 Dérivés de triazolopyridine utilisés comme inhibiteurs de la p38 map kinase

Publications (1)

Publication Number Publication Date
TN2011000380A1 true TN2011000380A1 (en) 2013-03-27

Family

ID=42232647

Family Applications (1)

Application Number Title Priority Date Filing Date
TN2011000380A TN2011000380A1 (en) 2009-02-17 2011-08-03 Triazolopyridine derivatives as p38 map kinase inhibitors

Country Status (19)

Country Link
US (1) US8557797B2 (fr)
EP (1) EP2398798A1 (fr)
JP (1) JP2012517992A (fr)
KR (1) KR20110116030A (fr)
CN (2) CN102395586A (fr)
AU (1) AU2010215261A1 (fr)
BR (1) BRPI1005327A2 (fr)
CA (1) CA2752693A1 (fr)
CL (1) CL2011001977A1 (fr)
CO (1) CO6420344A2 (fr)
EA (1) EA201190119A1 (fr)
IL (1) IL214658A0 (fr)
MA (1) MA33128B1 (fr)
MX (1) MX2011008496A (fr)
PE (1) PE20120655A1 (fr)
SG (1) SG174134A1 (fr)
TN (1) TN2011000380A1 (fr)
WO (1) WO2010094956A1 (fr)
ZA (1) ZA201105993B (fr)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5524071B2 (ja) * 2007-10-24 2014-06-18 メルク・シャープ・アンド・ドーム・コーポレーション 複素環フェニルアミドｔ型カルシウムチャネルアンタゴニスト
GB201009731D0 (en) * 2010-06-10 2010-07-21 Pulmagen Therapeutics Inflamma Kinase inhibitors
US9029378B2 (en) 2011-07-26 2015-05-12 Gruenenthal Gmbh Substituted bicyclic aromatic carboxamide and urea compounds as vanilloid receptor ligands
EP2788345B1 (fr) * 2011-12-09 2020-06-10 Chiesi Farmaceutici S.p.A. Derives de 4-hydroxy-1,2,3,4-tetrahydronaphtalen-1-yl uree et leur utilisation dans le traitement de, entre outre, maladies des voies respiratoires
EP2788349B1 (fr) * 2011-12-09 2016-10-26 Chiesi Farmaceutici S.p.A. Inhibiteurs de kinase
AU2012347352B2 (en) 2011-12-09 2016-12-15 Chiesi Farmaceutici S.P.A. Kinase inhibitors
WO2014015056A2 (fr) * 2012-07-17 2014-01-23 Washington University Médicaments anti-mucus et leurs utilisations
US9573949B2 (en) * 2013-06-06 2017-02-21 Chiesi Farmaceutici S.P.A. Derivatives of [1, 2, 4] triazolo [4, 3-a] pyridine as P38—MAP kinase inhibitors
CN105377847A (zh) * 2013-06-06 2016-03-02 奇斯药制品公司 激酶抑制剂
BR112015029462A8 (pt) * 2013-06-06 2023-03-21 Chiesi Farm Spa Inibidores de quinase
GB201321742D0 (en) * 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
UY36390A (es) * 2014-11-05 2016-06-01 Flexus Biosciences Inc Compuestos moduladores de la enzima indolamina 2,3-dioxigenasa (ido), sus métodos de síntesis y composiciones farmacéuticas que los contienen
BR112017008809A2 (pt) 2014-11-05 2017-12-19 Flexus Biosciences Inc agentes imunorreguladores
US10342786B2 (en) 2017-10-05 2019-07-09 Fulcrum Therapeutics, Inc. P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD
CN111601593B (zh) 2017-10-05 2022-04-15 弗尔康医疗公司 P38激酶抑制剂降低dux4和下游基因表达以用于治疗fshd

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU650953B2 (en) 1991-03-21 1994-07-07 Novartis Ag Inhaler
JPH11508583A (ja) 1995-07-06 1999-07-27 ゼネカ・リミテッド ペプチド系のフィブロネクチン阻害薬
US6248713B1 (en) 1995-07-11 2001-06-19 Biogen, Inc. Cell adhesion inhibitors
YU25500A (sh) 1999-05-11 2003-08-29 Pfizer Products Inc. Postupak za sintezu analoga nukleozida
GB0028383D0 (en) 2000-11-21 2001-01-03 Novartis Ag Organic compounds
EP1241176A1 (fr) 2001-03-16 2002-09-18 Pfizer Products Inc. Dérivés de purine pour le traitement de l'ischémie
AU2002361992A1 (en) 2001-12-20 2003-07-09 Bayer Aktiengesellschaft 1,4-dihydro-1,4-diphenylpyridine derivatives
BRPI0407384A (pt) * 2003-02-14 2006-02-21 Pfizer Prod Inc piridinas-triazóis como compostos antiinflamatórios
SE0302487D0 (sv) 2003-09-18 2003-09-18 Astrazeneca Ab Novel compounds
EP2295426A1 (fr) 2004-04-30 2011-03-16 Bayer HealthCare, LLC Derives de pyrazolyl uree substitues utiles dans le traitement du cancer
EP1609789A1 (fr) 2004-06-23 2005-12-28 Eli Lilly And Company Derives de ureido-pyrazole et leur utilisation comme inhibiteurs de kinase
DK1761520T3 (da) 2004-06-23 2008-10-27 Lilly Co Eli Kinaseinhibitorer
GB0418015D0 (en) * 2004-08-12 2004-09-15 Pfizer Ltd New compounds
AP2326A (en) 2004-08-12 2011-11-24 Pfizer Triazolopyridinylsulfanyl derivatives as p38 map kinase inhibitors.
EP1781655A2 (fr) * 2004-08-18 2007-05-09 Pharmacia & Upjohn Company LLC Nouveaux composes de triazolopyridine pour le traitement d'inflammation
GB0502258D0 (en) 2005-02-03 2005-03-09 Argenta Discovery Ltd Compounds and their use
JP2009526037A (ja) * 2006-02-09 2009-07-16 ファイザー・リミテッド トリアゾロピリジン化合物
PT2057115E (pt) 2006-08-21 2012-12-26 Array Biopharma Inc Derivados de ácido fenoxifenilacético substituídos na posição
GB0902648D0 (en) 2009-02-17 2009-04-01 Argenta Discovery Ltd Pharmaceutical compounds and compositions

Also Published As

Publication number Publication date
US8557797B2 (en) 2013-10-15
WO2010094956A1 (fr) 2010-08-26
CN102395586A (zh) 2012-03-28
US20120088763A1 (en) 2012-04-12
EP2398798A1 (fr) 2011-12-28
SG174134A1 (en) 2011-10-28
BRPI1005327A2 (pt) 2019-09-24
IL214658A0 (en) 2011-09-27
CN103483338A (zh) 2014-01-01
AU2010215261A1 (en) 2011-09-08
MA33128B1 (fr) 2012-03-01
ZA201105993B (en) 2012-10-31
CA2752693A1 (fr) 2010-08-26
MX2011008496A (es) 2011-11-18
KR20110116030A (ko) 2011-10-24
EA201190119A1 (ru) 2012-05-30
PE20120655A1 (es) 2012-06-07
CO6420344A2 (es) 2012-04-16
JP2012517992A (ja) 2012-08-09
CL2011001977A1 (es) 2011-11-18

Similar Documents

Publication Publication Date Title
TN2011000380A1 (en) Triazolopyridine derivatives as p38 map kinase inhibitors
MX2012015023A (es) Derivado novedoso de nicotinamida o sal del mismo.
PH12012500752A1 (en) Benzimidazole-imidazole derivatives
MX2009002802A (es) Derivados de 2-aril-6-fenil-imidazo[1,2-a]piridinas, su preparacion y su aplicacion en terapeutica.
WO2021012049A8 (fr) Dérivés 2-morpholinopyridine substitués utilisés en tant qu'inhibiteurs de kinases atr
MY159239A (en) Urea derivatives that are kinase inhibitors, and their therapeutic use
AR065556A1 (es) Derivados de 3-(( 1,2,4) triazolo (4,3-a) piridin -7-il) benzamida
EA200970493A1 (ru) Макроциклические ингибиторы вируса гепатита с
EA201791254A1 (ru) Кристаллические сольваты и комплексы производных (1s)-1,5-ангидро-1-c-(3-((фенил)метил)фенил)-d-глюцитола с аминокислотами в качестве ингибиторов sglt2 для лечения диабета
GEP20166484B (en) Protein kinase inhibitors
MX2010003445A (es) Derivados de nicotinamida, su preparacion y su uso terapeutico.
EA201100115A1 (ru) Новые производные аденина
EA201101566A1 (ru) Производные имидазола и их применение в качестве модуляторов циклинзависимых киназ
RU2009125578A (ru) Новые замещенные диазаспиропиридиноновые производные для применения в лечении мсн-1-опосредованных заболеваний
ATE557014T1 (de) Neue substituierte indolin-2-on-derivate und ihre verwendung als p38-mitogenaktivierte kinasehemmer
MX2010006202A (es) Derivados de oxindol substituidos por amidometil y el uso de los mismos para el tratamiento de enfermedades dependientes de la vasopresina.
MX2010000658A (es) Derivados de pirimidina 934.
MX2016006685A (es) Compuestos heterociclicos de n-acilimino.
MX2008010884A (es) Acidos 4-fenil-tiazol-5-carboxilicos y amidas de acidos 4-fenil-tiazol-5-carboxilicos como inhibidores de la plk1.
TW200716531A (en) Cyclohexanesulfonyl derivatives as GLYT1 inhibitors to treat schizophrenia
DE602007001463D1 (de) Pyrimidin-, chinazolin-, pteridin- und triazinderivate
PH12012501004A1 (en) Pyridine-pyridinone derivatives, preparation and therapeutic use thereof
NO20085317L (no) Imidazoazepinonforbindelser
CO6321159A2 (es) Compuestos pirazina fusionados utiles para el tratamiento de enfermedades degenerativas e inflamatorias
AR083861A1 (es) OXAZOLIDINONAS COMO MODULADORES DE mGluR5 Y COMPOSICIONES FARMACEUTICAS QUE LOS CONTIENEN